Zai Lab Limited
NASDAQ:ZLABBiotechnology
Healthcare
$21.92 +3.42%
+$0.61 today
- Market cap
- $2.47B
- Beta
- 0.78
- P/E (TTM)
- -11.4
- EPS (TTM)
- -$0.16
52W Low $15.96High $41.20
Volume 0.61M
Average 0.87M
Income Statement
Follow revenue through to earnings.
Revenue
$460.16M
FY 2025 · Annual
+15.3% YoYOperating Income
-$223.57M
FY 2025 · Annual
Net Income
-$175.54M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 144.31M | 215.04M | 266.72M | 398.99M | 460.16M |
| Cost of Revenue | 52.24M | 74.02M | 95.82M | 147.86M | 191.08M |
| Gross Profit | 92.07M | 141.02M | 170.9M | 251.13M | 269.08M |
| Gross Margin | 63.8% | 65.6% | 64.1% | 62.9% | 58.5% |
| Research & Development | 573.31M | 286.41M | 265.87M | 234.5M | 220.9M |
| Selling, General & Admin | 218.83M | 258.97M | 281.61M | 298.74M | 277.61M |
| Operating Expenses | 792.14M | 545.38M | 537.48M | 533.25M | 492.65M |
| Depreciation & Amortization | 6.49M | 8.23M | 9.03M | 11.86M | 15.01M |
| EBITDA | (689.46M) | (434.84M) | (365.11M) | (242.99M) | (158.25M) |
| EBITDA Margin | -477.8% | -202.2% | -136.9% | -60.9% | -34.4% |
| Operating Income | (700.06M) | (404.36M) | (366.57M) | (282.12M) | (223.57M) |
| Operating Margin | -485.1% | -188.0% | -137.4% | -70.7% | -48.6% |
| Interest Income | 2.19M | 14.58M | 39.8M | 37.11M | 33.05M |
| Interest Expense | 0 | 0 | 0 | 2.25M | 5.21M |
| Other Income / Expenses | (3.35M) | (38.93M) | 31.95M | 25.01M | 45.11M |
| Income Before Tax | (703.41M) | (443.29M) | (334.62M) | (257.1M) | (178.46M) |
| Pre-Tax Margin | -487.4% | -206.1% | -125.5% | -64.4% | -38.8% |
| Income Tax Expense | 1.06M | 0 | 0 | 0 | (2.93M) |
| Net Income | (704.47M) | (443.29M) | (334.62M) | (257.1M) | (175.54M) |
| Net Margin | -488.2% | -206.1% | -125.5% | -64.4% | -38.1% |
| EPS (Basic) | (75.80) | (46.30) | (34.60) | (2.60) | (1.60) |
| EPS (Diluted) | (75.80) | (46.30) | (34.60) | (2.60) | (1.60) |
| 9.3M | 9.58M | 9.66M | 98.95M | 109.53M | |
| 9.3M | 9.58M | 9.66M | 98.95M | 109.53M |
ZLAB Earnings Waterfall · TTM
NASDAQ:ZLAB · Revenue to Net Income
Key Ratios
EPS$-1.79
Gross Margin56.7%
Net Margin-42.4%
P/E Ratio-13.5
P/S Ratio22.1
Analysis
$449.6M of revenue converted into -$188.2M of net income for the selected period. Gross margin is 56.7% and net margin is -42.4%, showing how much revenue survives after costs and taxes. EPS is $-1.79, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| D | D filing | Nov 9, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Oct 23, 2026 |
How much revenue does ZLAB generate?
Zai Lab Limited (ZLAB) reported $460.16M of revenue in fiscal 2025.
Is ZLAB profitable?
Zai Lab Limited (ZLAB) reported -$175.54M of net income, with a net margin of -38.1%.
Continue the stock analysis
Jump to another research area for this company.